Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses

AIDS Research and Human Retroviruses

Volumn 15, Issue 11, 1999, Pages 1011-1020

  Zheng, Lian ^a,b   Huang, Xiao L I ^a   Fan, Zheng ^a   Borowski, Luann ^a   Wilson, Cara C ^a,c,d   Rinaldo Jr , Charles R ^a,c,e  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; ENVELOPE PROTEIN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LAMIVUDINE; LIPOSOME; POL PROTEIN; VIRUS PROTEIN; ZALCITABINE; ZIDOVUDINE;

ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTION;

ADULT; ANTIGEN PRESENTATION; ANTIVIRAL AGENTS; BREFELDIN A; CELLS, CULTURED; CHLOROQUINE; COHORT STUDIES; DENDRITIC CELLS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; IMMUNOLOGIC MEMORY; LIPOSOMES; MALE; T-LYMPHOCYTES, CYTOTOXIC; VIRAL PROTEINS;

EID: 0033587658     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310520     Document Type: Article

References (49)

1. Cella M, Sallusto F, and Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10-16.
2. Steinman RM: Dendritic cells and immune-based therapies. Exp Hematol 1996;24:859-862.
3. Caux C, Vanbervliet B, Massacrier C, Azuma M, Okumra K, Lanier LL, and Banchereau J: B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 1994;180:1841-1847.
4. Hart DNJ, Starling GS, Calder VL, and Fernando NS: B7/BB1 is a leukocyte differentiation antigen on human dendritic cells induced by activation. Immunology 1993;79:616-620.
5. van Kooten C and Banchereau J: Function of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997:9: 330-337.
6. Young JW, Koulova L, Soergel SA, Clark EA, Steinman RM, and Dupont B: The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4 lymphocytes by human blood dendritic cells in vitro. J Clin Invest 1992; 90:229-237.
7. + blood dendritic cells are potent producers of IFN-α in response to in vitro HIV-1 infection. J Immunol 1994; 152: 4649-4662.
8. Ghanekar S, Zheng L, Logar A, Navratil J, Borowski L, Gupta P, and Rinaldo C: Cytokine expression by human peripheral blood dendritic cells stimulated in vitro with HIV-1 and herpes simplex virus. J Immunol 1996;157:4028-4036.
9. Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinman RM, Romani N, and Schuler G: Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 1996;26:659-668.
10. Kang K, Kubin M, Cooper KD, Lessin SR, Trinchieri G, and Rook AH: IL-12 synthesis by human Langerhans cells. J Immunol 1996;156:1402-1407.
11. + T cells. J Immunol 1995;154:5071-5079.
12. Elbe A and Stingl G: Dendritic cells as stimulator cells of MHC class I-restricted immune responses. Adv Exp Med Biol 1995;378:341-345.
13. Schuler G and Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997; 186: 1183-1187.
14. Young JW and Inaba K: Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996;183:7-11.
15. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature (London) 1998;392:245-252.
16. Girolomoni G and Ricciardi-Castagnoli P: Dendritic cells hold promise for immunotherapy. Immunol Today 1997;18:102-104.
17. Wong J: Dendritic cells reach out to the clinic. Nature Med 1997;3:129.
18. Kundu S, Katzenstein D, Valentine FT, Spino C, Efron B, and Merigan TC: Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: Relationship to cellular immune responses. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:269-274.
19. Chen W, Carbone FR, and McCluskey J: Electroporation and commercial liposomes efficiently deliver soluble protein into the MHC class I presentation pathway: Priming in vitro and in vivo for class I-restricted recognition of soluble antigen. J Immunol Methods 1993;160:49-57.
20. Collins DS, Findlay K, and Harding CV: Processing of exogenous liposome-encapsulated antigens in vivo generates class I MHC-restricted T cell responses. J Immunol 1992;148:3336-3341.
21. Lawman MJ, Naylor PT, Huang L, Courtney RJ, and Rouse BT: Cell-mediated immunity to herpes simplex virus: Induction of cytotoxic T lymphocyte response by viral antigens incorporated into liposomes. J Immunol 1981;126:304-308.
22. Moore M, Carbone FR, and Bevan MJ: Induction of a soluble protein into the class I pathway of antigen processing and presentation. Cell 1988;54:777-785.
23. Reddy R, Zhou F, Nair S, Huang L, and Rouse BT: In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J Immunol 1992;148:1585-1589.
24. Walker C, Selby M, Erickson A, Cataldo D, Valensi J, and Van Nest G: Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc Natl Acad Sci USA 1992;89:7915-7918.
25. Zhou F and Huang L: Liposome-mediated cytoplasmic delivery of proteins: An effective means to access the MHC class I-restricted antigen presentation pathway. J Immunol Methods 1994;4: 229-235.
26. Zhou F, Rouse BT, and Huang L: An improved method of loading pH-sensitive liposomes with soluble proteins for class I restricted antigen presentation. J Immunol Methods 1991;145: 143-152.
27. Zhou F, Rouse BT, and Huang L: Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles. J Immunol 1992;149:1599-1604.
28. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, and Rothbard JB: Induction of soluble proteins into the MHC class I pathway by conjugation to an HIV Tat peptide. J Immunol 1997;159:1666-1668.
29. Nair S, Babu JS, Dunham RG, Kanada P, Burke RL, and Rouse BT: Induction of primary, antiviral cytotoxic, and proliferation responses with antigens administrated via dendritic cells. J Virol 1993;67:4062-4069.
30. Nair S, Zhou F, Reddy R, Huang L, and Rouse BT: Soluble proteins delivered to dendritic cells via pH-sensitive liposome induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med 1992;175:609-612.
31. Giorgi JV, Cheng HL, Margolick JB, Bauer KD, Ferbas J, Waxdal M, Schmid I, Hultin LE, Jackson AL, Park L, and Taylor JMG: Quality control in the flow cytometric measurement of T-lymphocyte subsets: The Multicenter AIDS Cohort Study experience. Clin Immunol Immunopathol 1990;55:173-186.
32. Fan Z, Huang X, Zheng L, Wilson C, Borowski L, Liebmann J, Gupta P, Margolick J, and Rinaldo C: Cultured blood dendritic cells retain HIV-1 antigen-presenting capacity for CTL during progressive HIV infection. J Immunol 1997;15:4973-4982.
33. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PD, Steinman RM, and Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
34. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, and Goldberg AL: Inhibitors of the proteasome block nonlysosomal protein degradation and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-771.
35. Yewdell JW and Bennink JR: Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. Science 1989;244:1072-1075.
36. Huang X-L, Fan Z, Liebmann J, and Rinaldo C: Detection of human immunodeficiency virus type 1-specific memory T lymphocytes in freshly donated and frozen-thawed peripheral blood mononuclear cells. Clin Diag Lab Immunol 1995;678-684.
37. McMichael AJ and Walker BD: Cytotoxic T lymphocyte epitopes: implications for HIV vaccines. AIDS 1994;8:S155-S173.
38. Rinaldo CR Jr, Huang X-L, Fan Z, Margolick J, Al Shboul Q, McMahon D, Riddler S, Day R, and Mellors J: Enhancement of anti-HIV-1 cytotoxic T lymphocyte reactivity after combination antiretroviral therapy in advanced stage HIV-1 infected patients. Submitted (1999).
39. Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, Sodroski J, Morgado M, Galvao-Castro B, von Briesen H, Bedows S, Weber J, Sharp PM, Shaw GM, and the WHO and NIAID Networks for HIV Isolation and Characterization: Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and characterization. J Virol 1996;70:1651-1667.
40. Cao H, Kanki P, Sankalé JL, Dieng-Sarr A, Mazzara GP, Kalams SA, Korber B, Mboup S, and Walker BD: Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development. J Virol 1997;71:8615-8623.
41. Finzi D, Hermankova M, Pierson T, Carryth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, and Siliciano RF: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
42. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, and Richman DD: Recovery of replication competent HIV despite prolonged suppression of plasma viremia. Science 1997;278: 1291-1295.
43. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, and Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996;2:52-58.
44. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, and Schadendorf D: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 1998;4:328-332.
45. Dupuis M, Peshwa MV, Benike C, Kundu SK, Engleman EG, Van Schooten WCA, and Merigan TC: Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals. AIDS Res Hum Retroviruses 1997;13:33-39.
46. Condon C, Watkins SC, Celluzzi CM, Thompson K, and Falo LD JR: DNA-based immunization by in vivo transfection of dendritic cells. Nature Med 1996;2:1122-1128.
47. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, and Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-1450.
48. Yuda T, Maruyama K, and Iwatsuru M: Prolongation of liposome circulation time by various derivatives of polyethyleneglycols. Biol Phar Bull 1996;19:1347-1351.
49. Zheng L, Huang L, Watkins S, Stolz D, Huang X-L, Fan Z, and Rinaldo C: Lysosme-mediated cytoplasmic delivery of proteins to human dendritic cells. Submitted (1999).